Hemoglobin as an independent prognostic factor in the radiotherapy of head and neck tumors

被引:2
|
作者
Schäfer, U [1 ]
Micke, O [1 ]
Müller, SB [1 ]
Schüller, P [1 ]
Willich, N [1 ]
机构
[1] Univ Hosp Munster, Dept Radiotherapy, D-48129 Munster, Germany
关键词
head and neck tumor; anemia; irradiation; SQUAMOUS-CELL CARCINOMA; ERYTHROPOIETIN INCREASES HEMOGLOBIN; LOCALLY ADVANCED HEAD; RADIATION-THERAPY; RECURRENT HEAD; SIMULTANEOUS RADIOCHEMOTHERAPY; PRETREATMENT HEMOGLOBIN; CLINICAL-TRIALS; SYSTEMIC LEVELS; ORAL-CAVITY;
D O I
10.1007/s00066-003-1117-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The purpose of this study was to analyze the prognostic value of baseline hemoglobin levels before radiotherapy in patients with head and neck tumors. Patients and Methods: In a retrospective study with a median follow-up of 43 months, we analyzed the results of 214 patients irradiated for head and neck cancer between January 1, 1990 and January 1, 1998 (180 men and 34 women; median age 58 years). The treatment concept consisted in adjuvant radiotherapy in 58 patients, 77 patients received definitive radiochemotherapy, 42 patients definitive radiotherapy, and 37 patients reirradiation for in-field recurrence. Baseline hemoglobin values were divided in four groups of the same patient number (quartiles). Several known prognostic factors Like sex, age, tumor stage, histologic grading, performance status, and treatment scheme were analyzed for their influence on overall and event-free survival and correlated with pretreatment hemoglobin values (Kaplan-Meier method). In addition, univariate und multivariate Logistic regression analyses were carded out to evaluate the effect of baseline hemoglobin on response rates. Results: The median survival (event-free survival) of all patients amounted to 15 months (10 months). 25%, 50%, and 75% of patients had hemoglobin values < 11.2 g/dl, < 12.7 g/dl., and < 13.9 g/dl., respectively. In the univariate analysis, the following variables were significant prognostic factors for overall/event-free survival (Log-rank test): treatment concept (p < 0.001/ p < 0.001), tumor stage (p < 0.001/p < 0.001), general condition (p < 0.001/p < 0.001), and pretreatment hemoglobin (p = 0.014/p = 0.05). Muttivariate analysis (Cox) proved these parameters to be independent of each other. In addition, response rate after radiation showed a strong association between hemoglobin and Local control probability (p = 0.02). Conclusion: In this retrospective analysis, baseline hemoglobin Level was shown to be an independent significant prognostic factor in radiotherapy of head and neck cancer patients. Therefore, the value of tumor anemia as a prognostic factor should be emphasized more.
引用
收藏
页码:527 / 534
页数:8
相关论文
共 50 条
  • [21] Pretreatment lymphocyte-to-monocyte ratio as an independent prognostic factor for head and neck cancer
    Kano, Satoshi
    Homma, Akihiro
    Hatakeyama, Hiromitsu
    Mizumachi, Takatsugu
    Sakashita, Tomohiro
    Kakizaki, Tomohiko
    Fukuda, Satoshi
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2017, 39 (02): : 247 - 253
  • [22] Parotid metastasis - An independent prognostic factor for head and neck cutaneous squamous cell carcinoma
    Ch'ng, S.
    Maitra, A.
    Lea, R.
    Brasch, H.
    Tan, S. T.
    JOURNAL OF PLASTIC RECONSTRUCTIVE AND AESTHETIC SURGERY, 2006, 59 (12): : 1288 - 1293
  • [23] Basaloid Squamous Cell Carcinoma is Not an Independent Adverse Prognostic Factor in Head and Neck Cancer
    Gordon, C. A.
    McDonald, M. W.
    Moore, M. G.
    Brigance, J. S.
    Clark, R. S.
    Weisberger, E. C.
    Summerlin, D. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S177 - S177
  • [24] Prognostic Worth of Epidermal Growth Factor Receptor (EGFR) in Patients with Head and Neck Tumors
    Barnes, Precious
    Yeboah, F. A.
    Zhu, Jinling
    Saahene, Roland Osei
    Obirikorang, Christian
    Adinortey, Michael Buenor
    Amoani, Benjamin
    Kyei, Foster
    Akakpo, Patrick
    Awuku, Yaw Asante
    JOURNAL OF CANCER EPIDEMIOLOGY, 2020, 2020
  • [25] Cervicofacial Rhytidectomy After Radiotherapy for Head and Neck Tumors
    Wudel, Justin M.
    Novis, Sarah
    Baker, Shan R.
    Kim, Jennifer C.
    Moyer, Jeffrey S.
    JAMA FACIAL PLASTIC SURGERY, 2016, 18 (01) : 9 - 14
  • [26] Analysis of osteoradionecrosis after radiotherapy of head and neck tumors
    Pigorsch, S. U.
    Pashova, M.
    Kehl, V.
    Wolff, K. -D.
    Molls, M.
    Hohlweg-Majert, B.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2009, 185 : 95 - 95
  • [27] RESPONSE TO RADIOTHERAPY OF HEAD AND NECK TUMORS IN AIDS PATIENTS
    HOMMEL, DJ
    BROWN, ML
    KINZIE, JJ
    AMERICAN JOURNAL OF SURGERY, 1987, 154 (04): : 443 - 446
  • [28] HYPERFRACTIONATED RADIOTHERAPY IN 56 PATIENTS WITH TUMORS OF HEAD AND NECK
    CASTERA, D
    LEGROS, M
    MOUILLET, J
    JOURNAL DE RADIOLOGIE D ELECTROLOGIE ET DE MEDECINE NUCLEAIRE, 1978, 59 (11): : 611 - 614
  • [29] PUBERTAL ANOMALIES FOLLOWING RADIOTHERAPY FOR HEAD AND NECK TUMORS
    CZERNICHOW, P
    BRAUNER, R
    RAPPAPORT, R
    CLINICAL AND INVESTIGATIVE MEDICINE-MEDECINE CLINIQUE ET EXPERIMENTALE, 1987, 10 (04): : A44 - A44
  • [30] ENDOCRINE COMPLICATIONS AFTER RADIOTHERAPY FOR TUMORS OF THE HEAD AND NECK
    SAMAAN, NA
    SCHULTZ, PN
    YANG, KPP
    VASSILOPOULOUSELLIN, R
    MAOR, MH
    CANGIR, A
    GOEPFERT, H
    JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1987, 109 (03): : 364 - 372